Fecha de publicación
Nº de solicitud
|1.||WO||WO/2013/184010 - FORMATION METHOD OF A MIDDLE EAR PROSTHESIS||12.12.2013||
|PCT/PL2013/000069||AKADEMIA GÓRNICZO-HUTNICZA||ZIĄBKA, Magdalena|
The process of preparing a middle ear prosthesis of polymeric material by injection moulding technology according to the presented invention is characterized by drying the thermoplastic polymer granules, preferably high density polyethylene or polyamide or polysulphone, at a temperature in the range of 60 to 150°C for a period of 2 to 8 hours. Subsequently granules are plasticized and then injected at a temperature between 180 and 400°C into the mold heated to a temperature between 60 and 150°C. Then obtained moulder is cooled and in the final stage it is hermetically packed in a vacuum and sterilized. In addition, the granules of the thermoplastic polymer composite are used, obtained by addition of bactericidal additive introduced into the thermoplastic polymer granules, preferably a silver powder with a particle size from 15 to 100 nm, in an amount of 0.1 - 3 wt %.
|2.||WO||WO/2013/184011 - THERAPEUTIC VACCINE FOR TREATMENT OF DIABETES TYPE 1 IN CHILDREN, APPLICATION OF THE CELL SORTER AND THE METHOD OF MULTIPLYING TREG CELLS TO PRODUCE THERAPEUTIC VACCINE FOR TREATMENT OF DIABETES TYPE 1||12.12.2013||
|PCT/PL2013/000072||GDANSKI UNIWERSYTET MEDYCZNY||TRZONKOWSKI, Piotr|
The gist of the invention consists in the therapeutic vaccine for treatment of diabetes type 1 in children, which contains - Treg cells CD3(+)CD4(+)CD25(high)CD127(-). Claimed too is the cell sorter used to produce the vaccine and the method of multiplying Treg cells in vitro.
|3.||WO||WO/2013/184012 - METHOD FOR PURIFICATION OF AMMONIA, MIXTURES OF NITROGEN AND HYDROGEN, OR NITROGEN, HYDROGEN AND AMMONIA||12.12.2013||
|PCT/PL2013/000075||POLITECHNIKA WARSZAWSKA||MACULEWICZ, Sławomir, Andrzej|
Method for purification of ammonia or mixtures of nitrogen and hydrogen, or nitrogen, hydrogen and ammonia, according to which: a) ammonia or a mixture of gases under pressure of from 0.1 to 25 MPa is passed through a column packed with aluminium oxide with a large specific surface area; b) the ammonia or mixture of gases is then passed through a column packed with CaO, NaOH, KOH or an NaOH/KOH melt, separately or in a mixture, at 20 to 70°C and under pressure of from 0.1 to 25 MPa; c) next, the ammonia or mixture of gases is passed through a column packed with activated carbon having a specific area of 100÷3000 m2 /g with sodium, potassium, caesium, magnesium, calcium, strontium, barium or cerium nitrates(V) or nitrates(III) deposited on its surface, separately or in a mixture; the aforementioned steps being realised in a serial process at a gas stream flow rate in the range of 100 dm3/h to 1000 m3/h.
|4.||WO||WO/2013/184013 - DOUBLE-SIDED USB TYPE A SOCKET||12.12.2013||
|PCT/PL2013/000076||JĘDRZEJ BLAUT DESIGN||BLAUT, Jędrzej|
The object of the invention are double- sided USB type A sockets that allow for easy insertion of USB type A plugs, regardless of their orientation relative to the socket.
|5.||WO||WO/2013/180588 - METHOD OF APPLYING A PROTECTIVE CLADDING, PARTICULARLY TO GAS-TIGHT MEMBRANES OF ENERGY BOILERS||05.12.2013||
|PCT/PL2013/000070||PLASMA SYSTEM S.A.||BOREK, Aleksander|
A method of applying a protective cladding, particularly to gas-tight membranes of energy boilers involves coupling of two gas-tight membranes (2) together, and then soaking a pair of gas-tight membranes (2) coupled together at 300°C to 800°C, favorably at around 700°C; afterwards, the membrane (2) surface where a cladding (1) is to be applied is cleaned, a pair of gas-tight membranes (2) coupled together is mounted on a positioner and then preheated up to 80°C to 600°C, favorably to around 300°C-450°C, and then the cleaned and preheated surface of a pair of gas- tight membranes (2) coupled together is covered with a protective cladding (1), wherein a protective cladding is applied at a thickness of 0.1 mm to 3.00 mm, favorably around 0.6 mm, and then the entire pair of gas-tight membranes (2) coupled together with a cladding (2) is finally soaked at 300°C to 800°C, favorably at around 700°C, and the set temperature is maintained for 10 minutes to 600 minutes, favorably for 15 minutes to 30 minutes, and finally, gas-tight membranes (2) with a cladding are uncoupled.
|6.||WO||WO/2013/180587 - Pressure tank||05.12.2013||
|PCT/PL2012/050017||ELPIGAZ SP. Z O.O.||JARZYŃSKI, Grzegorz|
Subject of the invention is a pressure tank, especially extended and toroidal, with different lengths in X, Y, Z axes, containing shells connected with more than one connecting coupler, equipped with connector pipes for tank fittings, brackets for tank and cover fixing, cover of tank fittings, inner shells, inner jackets, partitions, characterized in that the outer, upper shell (1) with outer, lower shell (2) create outer tank shell, having rectangular cross-sections with rounded corners, whereas inner jackets (6A, 6B) are connected with inner shells (4A, 4B, 5A, 5B) and/or outer shells (1, 2), beneficially inner shells are connected with middle tubes (7A, 7B, 7N), creating central couplers (L1, L2) of the tank, beneficially separated by partition (10), and connector pipes of tank fittings (9) are welded to tank walls in this way that the thickness of outer wall of connector pipe is between 0,4 to 1,8 of the thickness of tank elements.
|7.||WO||WO/2013/180585 - NANOPRODUCT COMPRISING LACTOBACILLUS REUTERI DAN080 USEFUL IN PROPHYLAXIS AND MEDICINE, BOTH HUMAN AND VETERINARY AND MEDICAL USE OF THE SAME||05.12.2013||
|PCT/PL2012/000039||KRUSZEWSKA, Danuta||KRUSZEWSKA, Danuta|
The invention relates to a nanoproduct useful in prophylaxis and medicine, both human and veterinary as well as to a medical use of the same. The invention discloses Lactobacillus reuteri DAN080 strain with deposit number DSM 15693 for use in medicine. The various forms of preparations comprising the Lactobacillus reuteri DAN080 strain with deposit number DSM 15693 are disclosed for use in medicine as therapeutic and prophylactic agent, especially as an antimicrobial agent, in prophylaxis and treatment of medical conditions developing as a result of infections caused by bacteria, fungi, and other pathogens of the gastrointestinal tract, body surface, and other systems, such as urogenital system, respiratory system, in vertebrates or as a therapeutic and/or prophylactic agent for the treatment and prevention of development of gout (podagra) and/or for increasing the activity of lysozyme in an organism of vertebrate, especially human, other mammal or bird. Also the medical instruments such as catheters and hygienic articles including Lactobacillus reuteri DAN080 strain with deposit number DSM 15693 culture products are disclosed.
|8.||WO||WO/2013/180586 - CONTAINER FOR TRANSPORT OF PRODUCTS, ESPECIALLY IN THE FORM OF COILS||05.12.2013||
|PCT/PL2012/000093||LAUDE. PL SPÓŁKA Z.O.O.||WITCZAK, Marcin|
The present invention is a container for the transport of products, particularly in the form of coils, comprising a floor (1), two side walls (2), a front wall (3), two doors (4) and a removable rigid roof (5) with a fastening mechanism. The floor (1) is equipped with movable supports with a fastening mechanism, grouped in at least one pair, located along its longer axis of symmetry, opposite to each other. In the closed position, the supports form a horizontal plane with the floor (1), while in the open position, they form a trough. The pivoting support, forming part of one pair consists of a flap (6) connected to the flap support (7) or a wide flap (8) connected to the wide flap support (9) or (10). The flap (6) and the wide flap (8) are movably connected with the floor (1) by means of hinges (11) located on one of the edges, whereas the flap (6) and the wide flap (8) are connected movably by the other edge by means of hinges (11) with the flap support (7) or the wide flap support (9 and 10). The floor (1) is equipped with two grooves (12), parallel to each other, and running through the whole length of it situated on both sides of the long axis of symmetry of the floor (1) and located below the flap supports (7) or the wide flap supports (9 and 10) lying horizontally.
|9.||WO||WO/2013/176559 - HYDRAULIC OPERATING DEVICE||28.11.2013||
|PCT/PL2013/000065||SIGMA S.A.||CHMIELEWSKI, Jacek|
The device consists of an actuator (1) supplied with hydraulic fluid through the valve block (2), wherein the actuator (1) is provided with a measuring unit (3) and two pressure sensors, the first sensor (9a) is mounted under the piston, and a second sensor (9b) is mounted above the piston. The first sensor (9a), the second sensor (9b), the measuring unit (3) and the valve block (2) are connected with the automatic control system (4) equipped with a transceiver (6). These elements are powered by the generator (10) via the battery bank (11), wherein the generator is powered by hydraulic fluid that drives the actuator (1). All elements of the device (8) are connected to the actuator's cylinder (1).
|10.||WO||WO/2013/176560 - AN INSULIN ANALOGUE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT, PHARMACEUTICAL COMPOSITION WITH PROLONGED THERAPEUTIC EFFECT, USE OF THE INSULIN ANALOGUE, DOSAGE METHOD AND METHOD OF TREATMENT OF DIABETES||28.11.2013||
|PCT/PL2013/000066||INSTYTUT BIOTECHNOLOGII I ANTYBIOTYKÓW||BOROWICZ, Piotr|
The invention relates to an insulin analogue or its pharmaceutically acceptable salt, pharmaceutical composition with prolonged therapeutic effect, application of the insulin analogue, dosage method and method of treatment of diabetes. In more detail, the solution pertains to compounds being stable insulin analogues which are pharmaceutically active and characterised by a prolonged, flat, truly peakless course of glucose concentration vs. time during repeated administration and which do not show strong 24 hours fluctuations of glucose concentration, or the so-called "sawteeth effect", during this time. Results of studies of compounds included in the scope of this application indicate an improvement in the effects of diabetes treatment by avoiding the hitherto occurring adverse influence of changes in glucose concentration throughout the entire day on a patient's organism, e.g. night hypoglycaemias, because truly peakless, long-acting insulin should reproduce correct endogenous insulin secretion in the therapy, as is provided by a healthy pancreas at a proper and constant 24 hours level.